Literature DB >> 10908315

The D2s dopamine receptor stimulates phospholipase D activity: a novel signaling pathway for dopamine.

S E Senogles1.   

Abstract

The D2 dopamine receptor isoforms signal to a variety of cellular effectors in both the central nervous system and periphery. Two alternative splice forms of the D2 dopamine receptor exist, the D2s (short) and D2l (long), which has an insertion of 29 amino acids in the third intracellular loop (). In cells of the anterior lobe of the pituitary, D2 dopamine receptors (both forms) are present on lactotroph cells coupled to the inhibition of adenylyl cyclase, activation of voltage-gated calcium channels, and inhibition of potassium channels. We describe here a novel signaling pathway for the D2s, which is the activation of phospholipase D (PLD). GH4C1 cells, a clonal line derived from a rat pituitary tumor, were stably transfected with the gene encoding the D2s, generating GH4-121 cells. Treatment of GH4-121 cells with a dopaminergic agonist resulted in activation of PLD in both a dose-dependent and time-dependent manner. This signaling pathway was not inhibited by prior treatment of cells with pertussis toxin at concentrations that ablate other D2s receptor signaling in this cell line. The stimulation of PLD activity by D2s appeared to correlate with the presence of a specific protein kinase C isoform, PKCepsilon. The D2s stimulation of PLD activity was blocked by preincubation of cells with C3 exoenzyme, indicating that the stimulation of PLD may involve Rho family members. The stimulation of PLD by dopaminergic agonists took place in the absence of any detectable stimulation of phosphoinositide metabolism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10908315     DOI: 10.1124/mol.58.2.455

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  17 in total

1.  Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.

Authors:  Rakesh Kumar; Lindsay R Riddle; Suzy A Griffin; Wenhua Chu; Suwanna Vangveravong; Janet Neisewander; Robert H Mach; Robert R Luedtke
Journal:  Neuropharmacology       Date:  2009-02-05       Impact factor: 5.250

2.  Metaplasticity of hypothalamic synapses following in vivo challenge.

Authors:  J Brent Kuzmiski; Quentin J Pittman; Jaideep S Bains
Journal:  Neuron       Date:  2009-06-25       Impact factor: 17.173

3.  Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling.

Authors:  Henry H Yin; David M Lovinger
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-12       Impact factor: 11.205

4.  Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on L-dopa dependent animal involuntary movements in rats.

Authors:  Lindsay R Riddle; Rakesh Kumar; Suzy A Griffin; Peter Grundt; Amy Hauck Newman; Robert R Luedtke
Journal:  Neuropharmacology       Date:  2010-09-17       Impact factor: 5.250

5.  Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.

Authors:  Leonardo Vieira Neto; Evelyn de O Machado; Raul M Luque; Giselle F Taboada; Jorge B Marcondes; Leila M C Chimelli; Leonardo Pereira Quintella; Paulo Niemeyer; Denise P de Carvalho; Rhonda D Kineman; Mônica R Gadelha
Journal:  J Clin Endocrinol Metab       Date:  2009-03-17       Impact factor: 5.958

Review 6.  Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?

Authors:  Richard B Mailman; Vishakantha Murthy
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

7.  The C. elegans D2-like dopamine receptor DOP-3 decreases behavioral sensitivity to the olfactory stimulus 1-octanol.

Authors:  Meredith J Ezak; Denise M Ferkey
Journal:  PLoS One       Date:  2010-03-02       Impact factor: 3.240

8.  D2 dopamine receptor activation facilitates endocannabinoid-mediated long-term synaptic depression of GABAergic synaptic transmission in midbrain dopamine neurons via cAMP-protein kinase A signaling.

Authors:  Bin Pan; Cecilia J Hillard; Qing-song Liu
Journal:  J Neurosci       Date:  2008-12-24       Impact factor: 6.167

Review 9.  Dopamine receptor signaling and current and future antipsychotic drugs.

Authors:  Kevin N Boyd; Richard B Mailman
Journal:  Handb Exp Pharmacol       Date:  2012

10.  Dopamine D2 receptor stimulation potentiates PolyQ-Huntingtin-induced mouse striatal neuron dysfunctions via Rho/ROCK-II activation.

Authors:  Carole Deyts; Beatriz Galan-Rodriguez; Elodie Martin; Nicolas Bouveyron; Emmanuel Roze; Delphine Charvin; Jocelyne Caboche; Sandrine Bétuing
Journal:  PLoS One       Date:  2009-12-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.